<DOC>
	<DOCNO>NCT02661854</DOCNO>
	<brief_summary>The purpose study evaluate efficient dose treatment rhinitis/rhinoconjunctivitis mite allergy</brief_summary>
	<brief_title>Dose Finding Treatment Rhinitis/Rhinoconjunctivitis Against Mite Allergy</brief_title>
	<detailed_description>Double blind placebo-controlled study . The subject receive medication 4 month .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Written inform consent Positive suggestive clinical history intermittent persistent moderate severe rhinitis /rhinoconjunctivitis , without moderate asthma , due Dermatophagoides pteronyssinus and/or Dermatophagoides farinae allergy Subjects positive skin pricktest ( wheal sixe &gt; 6 mm diameter ) Specific immunoglobulin E house dust mites &gt; 10 kU/L whose determination exceed 6 month prior inclusion visit Age 12 65 year Both gender Subjects capable give informed consent Subjects capable comply dose regimen Subjects receive immunotherapy last 5 year Subjects present sensitization another aeroallergens , consider clinically relevant clinical interference nasal provocation test . Subjects outside age range . Subjects previously receive immunotherapy treatment allergic rhinitis/rhinoconjunctivitis due mites allergen last 5 year . Subjects immunotherapy may absolute contraindication accord criterion immunotherapy Committee Spanish society Allergy Clinical Immunology , European Allergy Clinical Immunology Immunotherapy Subcommittee may also include . Subjects important symptom rhinoconjunctivitis /bronchial asthma suspension systemic antihistamine treatment contraindicate . Subjects persistent severe control asthma , force expiratory volume ( FEV ) &lt; 70 respect reference value spite appropriate pharmacological treatment time inclusion trial . Subjects required oral corticosteroid 12 week previous inclusion trial . Subjects previously submit serious secondary reaction skin prick test Subjects treatment beta blocker . Unstable subject clinical point view ( respiratory infection , febrile , acute urticaria , etc . ) time inclusion clinical trial Subject chronic urticaria last 2 year hereditary angioedema . Subjects pathology ( hyperthyroidism , hypertension , heart disease , etc . ) contraindicate . Subjects disease associate rhinitis/rhinoconjunctivitis , potential severity could interfere treatment followup ( epilepsy , psychomotor deterioration , diabetes , malformation , multioperated , kidney disease , ... ) . Subjects autoimmune disease ( lupus , thyroiditis , etc . ) , tumor diagnosis immunodeficiency disease . Subject whose status prevent provide cooperation present severe psychiatric disorder . Subject know allergy component vaccine different mite allergen extract . Subjects low airway disease asthma emphysema bronchiectasis . Direct investigator 's relative . Pregnant woman risk pregnancy breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rhinitis / Rhinoconjunctivitis</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Mite</keyword>
	<keyword>Allergy</keyword>
</DOC>